BR112014014124A2 - Moduladores do receptor de estrogênio fluorados e usos dos mesmos - Google Patents
Moduladores do receptor de estrogênio fluorados e usos dos mesmosInfo
- Publication number
- BR112014014124A2 BR112014014124A2 BR112014014124A BR112014014124A BR112014014124A2 BR 112014014124 A2 BR112014014124 A2 BR 112014014124A2 BR 112014014124 A BR112014014124 A BR 112014014124A BR 112014014124 A BR112014014124 A BR 112014014124A BR 112014014124 A2 BR112014014124 A2 BR 112014014124A2
- Authority
- BR
- Brazil
- Prior art keywords
- receptor modulators
- estrogen receptor
- fluorinated
- compounds
- estrogen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
- C07D311/60—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with aryl radicals attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
- C07D311/70—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with two hydrocarbon radicals attached in position 2 and elements other than carbon and hydrogen in position 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
MODULADORES DO RECEPTOR DE ESTROGÊNIO FLUORADOS E USOS DOS MESMOS. A presente invenção refere-se a compostos que são moduladores do receptor de estrogênio. Da mesma forma descritos são composições farmacêuticas e medicamentos que incluem os compostos descritos aqui, bem como métodos de usar tais moduladores do receptor de estrogênio, sozinhos e em combinação com outros compostos, para tratar doenças ou condições que são mediadas ou dependentes dos receptores de estrogênio.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161570756P | 2011-12-14 | 2011-12-14 | |
PCT/US2012/069933 WO2013090836A1 (en) | 2011-12-14 | 2012-12-14 | Fluorinated estrogen receptor modulators and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112014014124A2 true BR112014014124A2 (pt) | 2017-08-22 |
Family
ID=48613247
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112014014124A BR112014014124A2 (pt) | 2011-12-14 | 2012-12-14 | Moduladores do receptor de estrogênio fluorados e usos dos mesmos |
Country Status (15)
Country | Link |
---|---|
US (2) | US9193714B2 (pt) |
EP (2) | EP2791133B1 (pt) |
JP (2) | JP6112625B2 (pt) |
KR (1) | KR20140101399A (pt) |
CN (1) | CN104114551B (pt) |
AU (1) | AU2012351942B2 (pt) |
BR (1) | BR112014014124A2 (pt) |
CA (1) | CA2857057A1 (pt) |
EA (1) | EA029559B1 (pt) |
HK (1) | HK1198165A1 (pt) |
IL (1) | IL232793A (pt) |
MX (1) | MX357496B (pt) |
PH (1) | PH12014501351A1 (pt) |
SG (1) | SG11201403002RA (pt) |
WO (2) | WO2013090836A1 (pt) |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102939287B (zh) | 2010-06-10 | 2016-01-27 | 塞拉根制药公司 | ***受体调节剂及其用途 |
US9193714B2 (en) | 2011-12-14 | 2015-11-24 | Seragon Pharmaceuticals, Inc. | Fluorinated estrogen receptor modulators and uses thereof |
MD20140054A2 (ro) | 2011-12-16 | 2014-10-31 | Olema Pharmaceuticals, Inc. | Compuşi noi de benzopiran, compoziţii şi utilizări ale acestora |
BR112015030595A2 (pt) | 2013-06-19 | 2017-07-25 | Seragon Pharmaceuticals Inc | moduladores de receptor de estrogênio de azetidina e usos dos mesmos |
WO2014205138A1 (en) * | 2013-06-19 | 2014-12-24 | Seragon Pharmaceuticals, Inc. | Estrogen receptor modulator and uses thereof |
SG11201607339VA (en) * | 2014-03-13 | 2016-10-28 | Hoffmann La Roche | Methods and compositions for modulating estrogen receptor mutants |
WO2015136016A2 (en) | 2014-03-13 | 2015-09-17 | F. Hoffmann-La Roche Ag | Therapeutic combinations with estrogen receptor modulators |
US9839625B2 (en) | 2014-11-06 | 2017-12-12 | Northwestern University | Inhibition of cancer cell motility |
KR20230113416A (ko) * | 2014-12-18 | 2023-07-28 | 에프. 호프만-라 로슈 아게 | 테트라하이드로-피리도[3,4-b]인돌 에스트로겐 수용체조절제 및 이의 용도 |
US20160175284A1 (en) * | 2014-12-18 | 2016-06-23 | Genentech, Inc. | Estrogen receptor modulators and uses thereof |
US9845291B2 (en) | 2014-12-18 | 2017-12-19 | Genentech, Inc. | Estrogen receptor modulators and uses thereof |
EA202192092A3 (ru) * | 2015-04-02 | 2022-03-31 | Ф. Хоффманн-Ля Рош Аг | Тетрагидро-пиридо[3,4-b]индоловые модуляторы эстрогеновых рецепторов и их применение |
JP6768711B2 (ja) | 2015-05-26 | 2020-10-14 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 複素環式エストロゲン受容体モジュレーター及びその使用 |
WO2017000125A1 (en) | 2015-06-29 | 2017-01-05 | Merck Sharp & Dohme Corp. | Purine inhibitors of human phosphatidylinositol 3-kinase delta |
AU2016301195B2 (en) | 2015-08-06 | 2022-09-01 | Dana-Farber Cancer Institute, Inc. | Targeted protein degradation to attenuate adoptive T-cell therapy associated adverse inflammatory responses |
KR20180071274A (ko) | 2015-10-01 | 2018-06-27 | 올레마 파마슈티컬스 인코포레이티드 | 테트라히드로-1H-피리도[3,4-b]인돌 항에스트로겐 약물 |
UA122348C2 (uk) | 2015-10-27 | 2020-10-26 | Сан Фарма Адвансед Ресьорч Компані Лімітед | Нові гетероциклічні антиестрогени |
MX2018007079A (es) | 2015-12-09 | 2018-11-12 | The Board Of Trustees Of Univ Of Illinois | Reguladores a la baja del receptor de estrogeno selectivo de benzotiofeno. |
BR112018015419B1 (pt) | 2016-02-05 | 2024-01-30 | Inventisbio Llc | Degradantes seletivos de receptor de estrogênio, seus usos, e composição farmacêutica |
KR102401841B1 (ko) | 2016-04-01 | 2022-05-25 | 리커리엄 아이피 홀딩스, 엘엘씨 | 에스트로겐 수용체 조절제 |
TW201803870A (zh) | 2016-04-20 | 2018-02-01 | 阿斯特捷利康公司 | 化學化合物 |
WO2017197036A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Spirocyclic degronimers for target protein degradation |
EP3455218A4 (en) | 2016-05-10 | 2019-12-18 | C4 Therapeutics, Inc. | C3 CARBON-BASED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION |
WO2017197055A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
JP7018026B2 (ja) | 2016-06-16 | 2022-02-09 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | ヘテロアリールエストロゲン受容体モジュレーター及びその使用 |
CN109843882A (zh) * | 2016-06-16 | 2019-06-04 | 豪夫迈·罗氏有限公司 | 四氢-吡啶并[3,4-b]吲哚***受体调节剂及其用途 |
US20180002344A1 (en) | 2016-06-16 | 2018-01-04 | Genentech, Inc. | Heteroaryl estrogen receptor modulators and uses thereof |
JP2019520379A (ja) | 2016-07-01 | 2019-07-18 | ジー1 セラピューティクス, インコーポレイテッド | ピリミジン系の抗増殖剤 |
WO2018019793A1 (en) | 2016-07-25 | 2018-02-01 | Astrazeneca Ab | N-(2-(4-((1r,3r)-3-methyl-2,3,4,9-tetrahydro-1h-pyrido[3,4-b]indol-1-yl)phenoxy)ethyl)propan-1-amine derivatives and related compounds as selective down-regulators of the estrogen receptor for treating cancer |
WO2018081168A2 (en) | 2016-10-24 | 2018-05-03 | The Board Of Trustees Of The University Of Illinois | Benzothiophene-based selective mixed estrogen receptor downregulators |
US10131663B2 (en) | 2016-10-24 | 2018-11-20 | Astrazeneca Ab | Chemical compounds |
WO2018108954A1 (en) | 2016-12-12 | 2018-06-21 | F. Hoffmann-La Roche Ag | Process for the preparation of 2-(3-(fluoromethyl)azetidin-1-yl)ethan-1-ol |
MX2019008158A (es) | 2017-01-06 | 2019-12-09 | G1 Therapeutics Inc | Terapia de combinacion para el tratamiento del cancer. |
CA3050337A1 (en) | 2017-01-30 | 2018-08-02 | Astrazeneca Ab | Estrogen receptor modulators |
US11311609B2 (en) | 2017-02-08 | 2022-04-26 | Dana-Farber Cancer Institute, Inc. | Regulating chimeric antigen receptors |
US10208011B2 (en) | 2017-02-10 | 2019-02-19 | G1 Therapeutics, Inc. | Benzothiophene estrogen receptor modulators |
RU2019142591A (ru) | 2017-06-29 | 2021-07-29 | Г1 Терапьютикс, Инк. | Морфологические формы g1t38 и способы их получения |
BR112020007576A2 (pt) | 2017-10-18 | 2020-09-24 | Novartis Ag | composições e métodos para degradação de proteína seletiva |
AU2019210129B2 (en) | 2018-01-22 | 2023-09-28 | Radius Pharmaceuticals, Inc. | Estrogen receptor-modulating compounds |
SG11202012171SA (en) | 2018-06-21 | 2021-01-28 | Hoffmann La Roche | Solid forms of 3-((1r,3r)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azetidin-3-yl)amino)phenyl)-3-methyl-1,3,4,9-tetrahydro-2h-pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol and processes for preparing fused tricyclic compounds comprising a substituted phenyl or pyridinyl moiety, including methods of their use |
CN113453679A (zh) | 2018-12-20 | 2021-09-28 | C4医药公司 | 靶向蛋白降解 |
US20220251152A1 (en) | 2019-04-24 | 2022-08-11 | Novartis Ag | Compositions and methods for selective protein degradation |
JP2022541938A (ja) | 2019-07-22 | 2022-09-28 | サン・ファーマ・アドバンスド・リサーチ・カンパニー・リミテッド | 選択的エストロゲン受容体分解剤 |
AU2020326691A1 (en) | 2019-08-06 | 2022-03-03 | Recurium Ip Holdings, Llc | Estrogen receptor modulators for treating mutants |
WO2022140744A1 (en) | 2020-12-23 | 2022-06-30 | Recurium Ip Holdings, Llc | Estrogen receptor modulators |
AU2022320615A1 (en) | 2021-07-26 | 2024-03-14 | Celcuity Inc. | 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea (gedatolisib) and its combinations for use in the treatment of cancer |
WO2024030968A1 (en) | 2022-08-03 | 2024-02-08 | Brystol-Myers Squibb Company | Compounds for modulating ret protein |
Family Cites Families (109)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5395842A (en) | 1988-10-31 | 1995-03-07 | Endorecherche Inc. | Anti-estrogenic compounds and compositions |
US5686465A (en) | 1988-10-31 | 1997-11-11 | Endorecherche Inc. | Sex steroid activity inhibitors |
US5254568A (en) | 1990-08-09 | 1993-10-19 | Council Of Scientific & Industrial Research | Benzopyrans as antiestrogenic agents |
DE69023906T2 (de) | 1990-08-09 | 1996-04-11 | Council Scient Ind Res | Benzopyrane und Verfahren zu deren Herstellung. |
US6060503A (en) * | 1991-12-02 | 2000-05-09 | Endorecherche, Inc. | Benzopyran-containing compounds and method for their use |
DK0635264T3 (da) | 1993-06-24 | 1997-10-20 | Lilly Co Eli | Anti-østrogene 2-phenyl-3-aroylbenzothiazepiner som hypoglykæmiske midler |
US5407947A (en) | 1993-11-05 | 1995-04-18 | Eli Lilly And Company | Methods for inhibiting bone loss using pyrolidine and piperidine substituted benzopyrans |
US5446061A (en) | 1993-11-05 | 1995-08-29 | Eli Lilly And Company | Methods for lowering serum cholesterol |
US5416098A (en) | 1993-12-30 | 1995-05-16 | Zymogenetics, Inc. | Method for treating dermatitis and related conditions |
US5389646A (en) | 1993-12-30 | 1995-02-14 | Zymogenetics, Inc. | Methods for treatment and prevention of bone loss using 2,3-benzopyrans |
US5681835A (en) | 1994-04-25 | 1997-10-28 | Glaxo Wellcome Inc. | Non-steroidal ligands for the estrogen receptor |
NZ272608A (en) | 1994-07-22 | 2000-05-26 | Lilly Co Eli | Inhibiting bone loss by administering a bisphosphonate and a second compound selected from various compounds, including 2-phenyl-3-aroylbenzothienes; bisphosphonate combination salts |
US5637598A (en) | 1994-11-18 | 1997-06-10 | Eli Lilly And Company | Methods of inhibiting bone loss |
US5446071A (en) | 1994-11-18 | 1995-08-29 | Eli Lilly And Company | Methods for lowering serum cholesterol |
US5980938A (en) | 1996-07-15 | 1999-11-09 | Eli Lilly And Company | Effect of compounds that suppress induction of plasminogen activator inhibitor 1 (PAI-1) |
EP0937060B1 (en) * | 1996-10-28 | 2002-12-11 | Novo Nordisk A/S | Cis-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes |
WO1999002513A1 (en) | 1997-07-09 | 1999-01-21 | Novo Nordisk A/S | Preparation of diaryl-benzopyrans |
WO1999002512A1 (en) | 1997-07-09 | 1999-01-21 | Novo Nordisk A/S | Dl-2,3-diaryl-2h-1-benzopyrans |
EE200000077A (et) | 1997-08-15 | 2000-12-15 | Duke University | Östrogeenist sõltuvate haiguste ja häirete vältimise ja ravi meetod |
US6326392B1 (en) | 1997-11-06 | 2001-12-04 | American Home Products Corporation | Anti-estrogen plus progestin containing oral contraceptives |
ID24568A (id) | 1997-11-06 | 2000-07-27 | American Home Prod | Kontrasepsi oral yang mengandung anti-estrogen plus progestin |
KR20010042373A (ko) | 1998-03-30 | 2001-05-25 | 린다 에스. 스티븐슨 | 핵 수용체 활성을 조절하는 방법 및 화합물 |
US6965850B2 (en) | 1998-03-30 | 2005-11-15 | The Regents Of The University Of California | Methods for modulating nuclear receptor coactivator binding |
US7005428B1 (en) | 1998-06-11 | 2006-02-28 | Endorecherche, Inc. | Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors |
US6465445B1 (en) | 1998-06-11 | 2002-10-15 | Endorecherche, Inc. | Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors |
CA2340343C (en) | 1998-08-14 | 2007-04-24 | Schering Corporation | Enantioselective synthesis |
US6262270B1 (en) * | 1998-08-14 | 2001-07-17 | Schering Corporation | Enantioselective synthesis |
AR021719A1 (es) | 1998-12-18 | 2002-07-31 | Schering Corp | Composicion farmaceutica oral antiestrogenica. |
US6638727B1 (en) | 1999-01-26 | 2003-10-28 | Cytyc Health Corporation | Methods for identifying treating or monitoring asymptomatic patients for risk reduction or therapeutic treatment of breast cancer |
US6716452B1 (en) | 2000-08-22 | 2004-04-06 | New River Pharmaceuticals Inc. | Active agent delivery systems and methods for protecting and administering active agents |
DE19916419B4 (de) | 1999-04-08 | 2005-06-16 | Schering Ag | Kombinationspräparat aus Vitamin-D-Metaboliten oder Vitamin-D-Analoga und einem Östrogenpartialagonisten zur Behandlung von Osteoporose |
HU230543B1 (hu) | 1999-07-06 | 2016-11-28 | Endorecherche, Inc. | Inzulinrezisztencia kezelésére és/vagy megakadályozására szolgáló gyógyszerkészítmények |
AU7896100A (en) | 1999-10-14 | 2001-04-23 | Endorecherche Inc. | Selective estrogen receptor modulators in the treatment or reduction of the riskof acquiring hypertension, cardiovascular diseases, and insulin resistance |
GB0000313D0 (en) | 2000-01-10 | 2000-03-01 | Astrazeneca Uk Ltd | Formulation |
CO5271696A1 (es) | 2000-01-12 | 2003-04-30 | Pfizer Prod Inc | Procedimiento para reducir la morbilidad y el riesgo de mortalidad |
CO5271697A1 (es) | 2000-01-12 | 2003-04-30 | Pfizer Prod Inc | Composiciones y procedimientos para el tratamiento de afecciones que responden a un aumento de testosterona |
CO5271709A1 (es) | 2000-01-12 | 2003-04-30 | Pfizer Prod Inc | Composiciones y procedimientos para el y tratamiento de afecciones que responden a estrogenos |
CO5251465A1 (es) | 2000-01-26 | 2003-02-28 | Pfizer Prod Inc | Composiciones y procedimientos para tratar la osteoporosis y reducir el colesterol |
KR20020073566A (ko) | 2000-01-28 | 2002-09-27 | 앙도르쉐르슈 인코포레이티드 | 에스트로겐과 배합된 선택적인 에스트로겐 수용체 조절자 |
WO2001063292A2 (en) | 2000-02-22 | 2001-08-30 | Board Of Regents, The University Of Texas System | Compositions and methods of use of het, a novel modulator of estrogen action |
DE10013782A1 (de) * | 2000-03-15 | 2001-10-18 | Schering Ag | 4-Fluoralkyl-2H-benzopyrane mit antiestrogener Wirksamkeit, Verfahren zu ihrer Herstellung, pharmazeutische Präparate, die diese enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln |
US6528681B2 (en) | 2000-04-05 | 2003-03-04 | Bristol-Meyers Squibb Pharma Company | Halogenated triphenylethylene derivatives as selective estrogen receptor modulators |
US20020013327A1 (en) | 2000-04-18 | 2002-01-31 | Lee Andrew G. | Compositions and methods for treating female sexual dysfunction |
US8119138B2 (en) | 2000-05-10 | 2012-02-21 | Signe Biopharma Inc. | Anti-estrogen and immune modulator combinations for treating breast cancer |
US7863011B2 (en) | 2000-05-10 | 2011-01-04 | Signe Biopharma, Inc. | Screening method for predicting susceptibility to breast cancer |
EP1177787A3 (en) | 2000-07-28 | 2003-09-10 | Pfizer Products Inc. | Use of an estrogen agonist/antagonist for treating cataracts |
ATE278421T1 (de) | 2000-08-11 | 2004-10-15 | Wyeth Corp | Verfahren zur behandlung eines östrogenrezeptor positives karzinoms |
US20020099013A1 (en) | 2000-11-14 | 2002-07-25 | Thomas Piccariello | Active agent delivery systems and methods for protecting and administering active agents |
NZ524104A (en) | 2000-09-08 | 2004-12-24 | Pharmacia Italia S | Exemestane as chemopreventing agent |
EP1192945A3 (en) | 2000-09-21 | 2004-03-03 | Pfizer Products Inc. | Use of an estrogen agonist/antagonist for treating osteoarthritis |
MXPA03003032A (es) | 2000-10-06 | 2003-06-06 | Biomedicines Inc | Terapia de combinacion para el tratamiento de una enfermedad sensible a los estrogenos. |
IL145838A (en) | 2000-10-16 | 2008-11-03 | Pfizer Prod Inc | Use of an estrogen agonist / antagonist to produce a drug for the treatment of vaginitis |
US6750213B2 (en) | 2000-10-19 | 2004-06-15 | Merck & Co., Inc. | Estrogen receptor modulators |
WO2002032373A2 (en) | 2000-10-19 | 2002-04-25 | Merck & Co., Inc. | Estrogen receptor modulators |
CN1469743A (zh) | 2000-10-19 | 2004-01-21 | ***受体调节剂 | |
US20040082557A1 (en) | 2001-01-26 | 2004-04-29 | Wajszczuk Charles Paul | Methods for treating estrogen-dependent disorders |
MXPA03006607A (es) | 2001-01-26 | 2003-09-22 | Upjohn Co | Metodo combinado para tratar trastornos dependientes de hormonas. |
AU781168B2 (en) | 2001-01-26 | 2005-05-12 | Pfizer Products Inc. | Method of treating certain cancers using an estrogen agonist/antagonist |
GB2374412A (en) | 2001-04-11 | 2002-10-16 | Karobio Ab | Hypertension treatment and assay |
SK602004A3 (en) | 2001-08-11 | 2004-11-03 | Bristol Myers Squibb Pharma Co | Selective estrogen receptor modulators |
AU2002330031B2 (en) | 2001-09-21 | 2007-07-05 | Merck & Co., Inc. | Androstanes as androgen receptor modulators |
EP1434786A4 (en) | 2001-10-03 | 2009-03-25 | Merck & Co Inc | ANDROSTAN-17-BETA-CARBOXAMIDE AS MODULATORS OF THE ANDROGEN RECEPTOR |
MXPA04003405A (es) | 2001-10-10 | 2004-06-18 | Pharmacia Italia Spa | Metodos para prevenir y tratar la perdida de hueso con compuestos esteroidales. |
WO2003034987A2 (en) | 2001-10-19 | 2003-05-01 | Merck & Co., Inc. | Androgen receptor modulators and methods of use thereof |
HUP0500103A3 (en) * | 2001-12-19 | 2009-01-28 | Ortho Mcneil Pharm Inc | Tetracyclic compounds containing oxygen and/or sulfur atom, process for the preparation of some of them, their use and pharmaceutical compositions containing them |
US7105679B2 (en) * | 2001-12-19 | 2006-09-12 | Kanojia Ramesh M | Heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators |
EP1465619A1 (en) | 2002-01-14 | 2004-10-13 | Nordic Bioscience A/S | Suppression of cartilage degradation via the estrogen receptor |
WO2003070253A1 (en) | 2002-02-21 | 2003-08-28 | Pantarhei Bioscience B.V. | Estrogenic component for treating decreased libido in women |
WO2003076660A1 (en) | 2002-03-13 | 2003-09-18 | F.Hoffmann-La Roche Ag | Method for selecting drug sensitivity-determining factors and method for predicting drug sensitivity using the selected factors |
BR0308355A (pt) | 2002-03-13 | 2005-01-25 | Merck & Co Inc | Composto ou um sal farmaceuticamente aceitável ou um seu enanciÈmero, métodos para modular uma função mediada pelo receptor de androgênio em um mamìfero em necessidade de tal modulação, para ativar a função do receptor de androgênio em um mamìfero em necessidade de tal ativação, para tratar uma condição em um mamìfero, e para tratar osteoporose em um mamìfero em sua necessidade, composição farmacêutica, métodos para aumentar a densidade mineral óssea em um mamìfero em necessidade disto, para reduzir o risco de fraturas vertebrais ou não vertebrais em um mamìfero em necessidade disto, e para produzir um marcador de modificação óssea em um mamìfero em necessidade disto, processo para produzir uma composição farmacêutica, e, método para tratar ou prevenir uma condição artrìtica em um mamìfero em necessidade disto |
US20030225132A1 (en) | 2002-04-11 | 2003-12-04 | Dininno Frank P. | Estrogen receptor modulators |
ES2350446T3 (es) | 2002-04-24 | 2011-01-24 | MERCK SHARP & DOHME CORP. | Moduladores de los receptores de estrógenos. |
JP4516839B2 (ja) | 2002-04-30 | 2010-08-04 | メルク・シャープ・エンド・ドーム・コーポレイション | アンドロゲン受容体修飾因子としての4−アザステロイド誘導体 |
MXPA04012419A (es) | 2002-06-25 | 2005-04-19 | Wyeth Corp | Uso de derivados de tio-oxindol en el tratamiento de condiciones relacionadas con la hormona. |
TW200404548A (en) | 2002-06-25 | 2004-04-01 | Wyeth Corp | Pharmaceutical composition containing cyclothiocarbamate derivatives in treatment of hormone-related conditions |
AU2003286757B2 (en) | 2002-11-01 | 2009-06-04 | Merck Sharp & Dohme Corp. | Carbonylamino-benzimidazole derivatives as androgen receptor modulators |
WO2004091488A2 (en) | 2003-04-14 | 2004-10-28 | Merck & Co., Inc. | Estrogen receptor modulators |
CN1784236A (zh) | 2003-05-07 | 2006-06-07 | 麦克公司 | 雄激素受体调节剂及其使用方法 |
SI1622630T1 (sl) | 2003-05-07 | 2012-12-31 | Osteologix A/S | Stroncijeva kombinacije za profilakso/zdravljenje patologij hrustanca in/ali kosti |
WO2005123193A2 (en) | 2004-06-17 | 2005-12-29 | Osteologix A/S | Treatments comprising strontium for rheumatic and arthritic diseases and pain |
US20040248989A1 (en) | 2003-06-05 | 2004-12-09 | Risto Santti | Method for the treatment or prevention of lower urinary tract symptoms |
CN1816528A (zh) | 2003-06-30 | 2006-08-09 | 麦克公司 | 作为雄激素受体调节剂的17-乙酰氨基-4-氮杂甾类衍生物 |
JP2007521293A (ja) | 2003-06-30 | 2007-08-02 | メルク エンド カムパニー インコーポレーテッド | アンドロゲン受容体モジュレータとしての17−アセトアミド−4−アザステロイド誘導体 |
JP2007521292A (ja) | 2003-06-30 | 2007-08-02 | メルク エンド カムパニー インコーポレーテッド | アンドロゲン受容体モジュレータとしての17−アセトアミド−4−アザステロイド誘導体 |
EP1641464A4 (en) | 2003-06-30 | 2008-05-14 | Merck & Co Inc | 17-ACETAMIDO-4-AZASTEROID DERIVATIVES AS MODULATORS OF THE ANDROGEN RECEPTOR |
CN1849120A (zh) | 2003-09-10 | 2006-10-18 | 默克公司 | 作为雄激素受体调节剂的17-杂环-4-氮杂甾类衍生物 |
CN1849126A (zh) | 2003-09-10 | 2006-10-18 | 默克公司 | 作为雄激素受体调节剂的17-杂环-4-氮杂甾族衍生物 |
ATE399775T1 (de) | 2003-10-08 | 2008-07-15 | Smithkline Beecham Corp | Triphenylethyleneverbindungen als selektive modulatoren des östrogenrezeptors |
EP1696925A4 (en) | 2003-10-31 | 2009-11-18 | Merck & Co Inc | 21-Heterocyclic 4-AZASTEROID DERIVATIVES AS ANDROGEN RECEPTOR MODULATORS |
WO2005073190A1 (en) | 2004-01-29 | 2005-08-11 | Eli Lilly And Company | Selective estrogen receptor modulators |
UA87854C2 (en) | 2004-06-07 | 2009-08-25 | Мерк Энд Ко., Инк. | N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators |
WO2005123130A2 (en) | 2004-06-17 | 2005-12-29 | Osteologix A/S | Improved treatments of rheumatic and arthritic diseases comprising combinations of a 5-lipoxygenase inhibitor |
CA2578852A1 (en) | 2004-09-03 | 2006-03-09 | Hormos Medical Corporation | Use of a selective estrogen receptor modulator for the manufacture of a pharmaceutical preparation for use in a method for the treatment or prevention of androgen deficiency |
CN106038572A (zh) | 2004-10-20 | 2016-10-26 | 恩多研究公司 | 性甾体前体单独或与选择性***受体调节剂联合用于预防和治疗绝经后女性的性功能障碍 |
WO2006084937A1 (en) | 2005-02-14 | 2006-08-17 | Leskelae Hannu-Ville | Method for diagnosing and treating women with increased response to hormonal replacement therapy |
US20070078114A1 (en) | 2005-09-02 | 2007-04-05 | Myriad Genetics, Incorporated | Combination therapy for alzheimer's disease and other diseases |
WO2007098090A2 (en) | 2006-02-17 | 2007-08-30 | Novacea, Inc. | Treatment of hyperproliferative diseases with n-oxides of estrogen receptor modulators |
US20080268041A1 (en) | 2007-04-23 | 2008-10-30 | Jens Hoffmann | Combination of progesterone-receptor antagonist together with none-steroidal antiestrogen for use in brca mediated diseases |
DE102007026877A1 (de) | 2007-06-08 | 2008-12-11 | Bayer Schering Pharma Aktiengesellschaft | Verwendung des Fibroblastenwachstumsfaktors 7 (Fgf7) und des Rezeptors Fgfr2b als Biomarker |
WO2009143309A2 (en) | 2008-05-21 | 2009-11-26 | Trustees Of Dartmouth College | Female reproductive tract and anal prophylaxes |
WO2010107474A1 (en) | 2009-03-16 | 2010-09-23 | The Research Foundation Of State University Of New York | Antiestrogens for breast cancer therapy |
US20100317635A1 (en) | 2009-06-16 | 2010-12-16 | Endorecherche, Inc. | Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators |
CN102939287B (zh) | 2010-06-10 | 2016-01-27 | 塞拉根制药公司 | ***受体调节剂及其用途 |
US8853423B2 (en) | 2010-06-17 | 2014-10-07 | Seragon Pharmaceuticals, Inc. | Indane estrogen receptor modulators and uses thereof |
DE102010030538A1 (de) | 2010-06-25 | 2011-12-29 | Bayer Schering Pharma Aktiengesellschaft | 6,7-Dihydro-5H-benzo[7]annulen-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln |
GB2483736B (en) | 2010-09-16 | 2012-08-29 | Aragon Pharmaceuticals Inc | Estrogen receptor modulators and uses thereof |
US9540361B2 (en) | 2010-12-24 | 2017-01-10 | Merck Sharp & Dohme B.V. | N-substituted azetidine derivatives |
US9193714B2 (en) | 2011-12-14 | 2015-11-24 | Seragon Pharmaceuticals, Inc. | Fluorinated estrogen receptor modulators and uses thereof |
MD20140054A2 (ro) | 2011-12-16 | 2014-10-31 | Olema Pharmaceuticals, Inc. | Compuşi noi de benzopiran, compoziţii şi utilizări ale acestora |
-
2012
- 2012-12-14 US US14/364,974 patent/US9193714B2/en active Active
- 2012-12-14 EA EA201491161A patent/EA029559B1/ru not_active IP Right Cessation
- 2012-12-14 US US14/364,993 patent/US9187460B2/en active Active
- 2012-12-14 BR BR112014014124A patent/BR112014014124A2/pt not_active Application Discontinuation
- 2012-12-14 WO PCT/US2012/069933 patent/WO2013090836A1/en active Application Filing
- 2012-12-14 AU AU2012351942A patent/AU2012351942B2/en not_active Ceased
- 2012-12-14 JP JP2014547528A patent/JP6112625B2/ja active Active
- 2012-12-14 MX MX2014007048A patent/MX357496B/es active IP Right Grant
- 2012-12-14 CA CA2857057A patent/CA2857057A1/en not_active Abandoned
- 2012-12-14 SG SG11201403002RA patent/SG11201403002RA/en unknown
- 2012-12-14 EP EP12857534.7A patent/EP2791133B1/en active Active
- 2012-12-14 CN CN201280069778.7A patent/CN104114551B/zh active Active
- 2012-12-14 JP JP2014547524A patent/JP2015500346A/ja active Pending
- 2012-12-14 EP EP12857161.9A patent/EP2791132A4/en not_active Withdrawn
- 2012-12-14 WO PCT/US2012/069926 patent/WO2013090829A1/en active Application Filing
- 2012-12-14 KR KR1020147018020A patent/KR20140101399A/ko not_active Application Discontinuation
-
2014
- 2014-05-26 IL IL232793A patent/IL232793A/en active IP Right Grant
- 2014-06-13 PH PH12014501351A patent/PH12014501351A1/en unknown
- 2014-11-18 HK HK14111641.4A patent/HK1198165A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
HK1198165A1 (en) | 2015-03-13 |
CA2857057A1 (en) | 2013-06-20 |
KR20140101399A (ko) | 2014-08-19 |
EP2791133A4 (en) | 2015-04-15 |
EA029559B1 (ru) | 2018-04-30 |
CN104114551A (zh) | 2014-10-22 |
JP2015500346A (ja) | 2015-01-05 |
SG11201403002RA (en) | 2014-07-30 |
EA201491161A1 (ru) | 2014-11-28 |
IL232793A (en) | 2016-09-29 |
PH12014501351B1 (en) | 2014-09-22 |
WO2013090829A1 (en) | 2013-06-20 |
EP2791132A4 (en) | 2015-08-05 |
EP2791133B1 (en) | 2019-04-17 |
IL232793A0 (en) | 2014-08-03 |
WO2013090836A1 (en) | 2013-06-20 |
US20140364427A1 (en) | 2014-12-11 |
JP6112625B2 (ja) | 2017-04-12 |
JP2015501847A (ja) | 2015-01-19 |
EP2791132A1 (en) | 2014-10-22 |
US9187460B2 (en) | 2015-11-17 |
AU2012351942A1 (en) | 2014-06-12 |
CN104114551B (zh) | 2017-01-18 |
AU2012351942B2 (en) | 2017-07-06 |
PH12014501351A1 (en) | 2014-09-22 |
EP2791133A1 (en) | 2014-10-22 |
US9193714B2 (en) | 2015-11-24 |
MX357496B (es) | 2018-07-11 |
US20150005286A1 (en) | 2015-01-01 |
MX2014007048A (es) | 2015-01-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112014014124A2 (pt) | Moduladores do receptor de estrogênio fluorados e usos dos mesmos | |
BR112012020558A2 (pt) | moduladores do receptor de androgênio e seus usos | |
BR112015022566A2 (pt) | composto e composição farmacêutica | |
BR112015030595A2 (pt) | moduladores de receptor de estrogênio de azetidina e usos dos mesmos | |
BR112015031903A2 (pt) | composto, sal farmaceuticamente aceitável do composto, composição farmacêutica e utilização de um composto | |
BR112013006395A2 (pt) | moduladores do receptor de estrogênio e seus usos. | |
UY35177A (es) | Novedosos derivados de bencimidazol como antagonistas de ep4 | |
CO6771417A2 (es) | Antagonistas del receptor de ácido lisofosfatidico y su uso en el tratamiento de fibrosis | |
UY35210A (es) | Inhibidores de autotaxina | |
BR112015001801A2 (pt) | métodos e composições para determinar a resistência à terapia de receptor de androgênio | |
EA201491530A1 (ru) | Модуляторы рецепторов эстрогенов и их применение | |
EA201270815A1 (ru) | Модуляторы рецепторов эстрогена и их применение | |
BR112017007123A2 (pt) | derivados de tetrahidroisoquinolina | |
BR112012007102A2 (pt) | compostos policíclicos como antagonistas de receptores do ácido lisofosfatpidico | |
NI201600071A (es) | Compuestos de inhibidor de autotaxina | |
BR112015009624A2 (pt) | inibidores de tirosina cinase de bruton | |
BR112014008294A2 (pt) | anticorpo anti c-met e usos do mesmo | |
BR112014026952A2 (pt) | derivados de aminopirimidina pirazol como moduladores lrrk2 | |
CL2014003388A1 (es) | Compuestos derivados de triazolona, como inhibidores de mpges-1; proceso de preparacion de dichos compuestos; composicion farmaceutica que los comprende, util para el tratamiento de inflamacion, asma, epoc, artritis, enfermedad de parkinson y enfermedades autoinmunes, entre otras enfermedades. | |
BR112013027774A2 (pt) | novos compostos como moduladores de proteína quinases | |
CO6480918A2 (es) | Antagonistas policíclicos de receptores de ácido lisofosfatídico. | |
BR112012004696A2 (pt) | compostos e composições como moduladores da atividade de tlr | |
ECSP16078782A (es) | Compuestos de isoindolinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados | |
UY35906A (es) | Novedosos derivados de bencimidazol como ligandos de ep4 | |
BR112012008004A2 (pt) | compostos e composições como moduladores da atividade de gpr119 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
B11E | Dismissal acc. art. 34 of ipl - requirements for examination incomplete | ||
B11T | Dismissal of application maintained [chapter 11.20 patent gazette] |